Title : Efficacy, safety, and immunogenicity of mRNA-1345 for respiratory syncytial virus prevention in adults: A systematic review
Abstract:
Background: Respiratory syncytial virus (RSV) is a major pathogen that causes respiratory illness in adults and most commonly affects populations with additional comorbidities or the elderly. RSV poses a significant risk for severe respiratory infections among adults. mRNA-1345 vaccine utilizes advanced mRNA technology. While mRNA vaccines have demonstrated considerable success in other infectious disease contexts, detailed evidence on the efficacy, safety, and immunogenicity of mRNA-1345 specifically for RSV among adults remains scarce.
Objective: We aimed to evaluate the effectiveness and safety profile of the mRNA-1345 vaccine in preventing RSV infections in adult populations.
Method: A search was conducted through PubMed and the Cochrane Library to identify randomized controlled trials examining the efficacy and safety of the mRNA-1345 vaccine against RSV. The review was conducted adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Results: The mRNA-1345 vaccine demonstrated an overall efficacy of 68.4% against RSV-associated respiratory illness (ARI) and 83.7% against RSV-associated lower respiratory tract disease (LRTD) with at least two signs or symptoms in individuals aged 60 and older. Concerning RSV-associated respiratory illness (ARI), the vaccine provided 78.5% protection against RSV-A and 51.7% against RSV-B strains. The vaccine's safety profile was comparable to a placebo, with mild to moderate adverse events like injection-site pain and fever. Adverse events were rare and equally distributed between the vaccine and placebo groups.
Conclusion: The mRNA-1345 vaccine has demonstrated significant benefits in preventing RSV-associated LRTD and ARI in adults 60 and older. Additionally, it has proven to have an acceptable safety profile across age groups, particularly in those aged 18-49 and 60 and above. The vaccine also elicited a robust immune response, with clear evidence of immunogenicity. Overall, the mRNA-1345 vaccine emerges as a promising candidate for adult vaccination.
Keywords: Respiratory Syncytial Virus, mRNA-1345 vaccine, RSV, adults, prevention strategy
Audience Take Away Notes:
- The latest development of mRNA-1345 vaccines, which have gained the spotlight following the mRNA COVID vaccine
- Recent availability and FDA approval for the mRNA-1345 vaccine for RSV in adults
- The burden of RSV in adults and infant age groups
- The safety profile. Efficacy and immunogenicity of the vaccine
